HOME >> MEDICINE >> NEWS
Novel antibiotic provides rapid relief from symptoms of tonsillitis/pharyngitis, study shows

Ketek (telithromycin), a novel compound from a new family of antibiotics, administered once daily for five days to patients suffering from tonsillitis/pharyngitis, provided equivalent clinical and bacteriological outcomes as those observed in patients receiving a 10-day course of treatment with penicillin V, a new study shows.

The more rapid symptom relief achieved with Ketek, the first antibiotic from the ketolide family to be developed for clinical use, may suggest a potential for a faster return to usual activities, and fewer days lost from work or school, for people with tonsillitis/pharyngitis resulting from group A b-haemoliytic streptococcus (GABHS) bacteria. GABHS is the most common bacterial cause of tonsillitis/pharyngitis.

The study results, reported today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Istanbul, Turkey, were among several scientific presentations involving Ketek.

"This is an important study as it demonstrates the clinical and bacteriological effectiveness and symptom relief of Ketek in treating what is a very common upper respiratory tract infection," said Dr. Joanne Chang, Aventis Pharma.

The double-blinded study enrolled 396 patients between the ages of 15 and 65 with clinical signs and symptoms of acute tonsillopharyngitis, and who either had a positive streptococcal A antigen test or a positive throat culture for GABHS. These patients were randomized (198 patients to each group) to receive either 800 mg once daily Ketek followed by placebo for five days, or penicillin V 500 mg three-times daily for 10 days. Clinical and bacteriological outcomes were assessed at post-therapy (days 16-21) and late post-therapy (days 38-45).

At the post-therapy visit, bacteriological outcome was satisfactory in 79.7 percent and 79.3 percent of patients, and clinical cure was achieved in 85.9 percent and 85.8 percent of patients in the Ketek (198 patients) and penicillin V (197
'"/>

Contact: Liz Rickard
elizabeth.rickard@ketchum.com
44-0-20-7611-3633
Ketchum
4-Apr-2001


Page: 1 2

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel drugs help solve Gleevec resistance
5. Novel imaging technique shows abnormal brain anatomy in children with ADHD
6. Novel drug-antidote strategy provides greater control of drug action
7. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
8. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
9. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
10. Novel findings about neovessel formation
11. Novel MRI technique provides clear images of blood flow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical health ... patients with dental emergencies at risk of losing a tooth or their smiles. Dr. ... , Common dental emergencies include:, , Avulsed or knocked-out teeth ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron ... accepting new dental patients and families in the North Metro Denver area. The new ... cleanings to cosmetic dentistry, and all in the most relaxing environment. , While some ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), ... latest addition to its growing list of Partner Firms. S.S. Nesbitt is ... Orlando to Huntsville and in between. , Harnessing the experience and insights of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016  Rich Pharmaceuticals, ... today announced a 1-for-100 reverse split of its issued ... opening of trading on Thursday, February 11, 2016. The ... under new CUSIP number 76303T308 and temporary ticker symbol ... commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
Breaking Medicine Technology:
Cached News: